Downregulation of the PI3K/Akt signaling pathway can significantly inhibit tumor activity, and simultaneously inhibiting the WNT/β-catenin pathway can enhance its effects in vitro and in vivo [100]. This evidence concerns the gene AKT1 and neoplasm.